Insilico Medicine’s IPO, Servier Pharma Deal

January 6, 2026

By Bio-IT World Staff 

January 6, 2026 | On December 30, Insilico Medicine successfully listed on the Hong Kong Stock Exchange. This initial public offering (IPO) raised a total of HKD 2.277 billion ($292 billion), achieving the largest biotech IPO in Hong Kong in 2025. 

“With this massively oversubscribed listing we set several world’s firsts further confirming Insilico’s validated leadership position in AI-powered drug discovery and development and the strength of our platform and pipeline. Insilico is dedicated to extending human productive longevity and this listing provides us with more resources to advance our mission,” said Alex Zhavoronkov, PhD, Founder and CEO, Chief Business Officer of Insilico Medicine in a press release about the listing. 

At the Bio-IT World Conference & Expo last year, Zhavoronkov outlined Insilico Medicine’s vision for helping people live longer, healthier lives and the company’s investments into validating their own platform.  

Insilico Medicine has built an integrated AI platform that spans target discovery, small molecule design, biologics, and clinical trial outcome prediction, he said. The company distinguishes itself by investing its own resources to validate its AI tools. "We actually bet a lot of money to actually see if the molecule works or not," Zhavoronkov noted, contrasting this approach with companies that rely solely on pharmaceutical partners to test their software. 

Following the IPO, Insilico plans to allocate approximately 48% of the net proceeds to fund further clinical research and development of our key clinical stage pipeline drug candidates, 20% to fund the research and development for early-stage drug discovery and development, 15% for development of new generative AI models and the associated validation research work, 12% for the further development and expansion of our automated lab, and 5% for working capital and other general corporate purposes.  

The IPO marks, “a new starting point for our deep integration of AI with life sciences and reshaping of the drug development paradigm”, said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine in the announcement. “We believe that the value of AI extends far beyond cost reduction and efficiency gains; it lies in continuously pushing the boundaries of foundational innovation. Support from the capital markets will help us further enhance our AI platform, expand our pipeline, improve R&D efficiency, and collaborate with global partners to accelerate the translation of innovative medicines. Guided by a long‑term vision and driven by technology, we are committed to transform AI into real productivity that improves human health.” 

Pharma Partners 

While Insilico prides itself on not relying on pharma partners for all of its funding, the company's business model involves developing novel drug candidates and then licensing them to pharmaceutical companies. Earlier this week, Insilico announced a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company governed by a foundation. This strategic alliance is focused on identifying and developing novel therapeutics for challenging targets in the oncology space by leveraging Insilico's proprietary AI platform, Pharma.AI. 

The Pharma.AI platform, launched in 2020, is commercialized as a modular software suite, and its collaboration network has expanded globally. Insilico has entered into software licensing collaborations with 13 of the world’s top 20 largest pharmaceutical companies to date and continuously iterates its algorithms, building proprietary multimodal data warehouses, and improving infrastructure and tooling.  

Under the terms of the agreement with Servier, Insilico will be eligible to receive up to $32 million in upfront and near-term R&D payments and will lead the AI-driven discovery and development of potential drug candidates that meet predefined criteria, while Servier will share the R&D expenses and lead clinical validation and commercialization processes. 

“This collaboration underscores Servier’s commitment to applying cutting-edge technologies to address unmet medical needs for the benefit of patients and reflects our confidence in Insilico’s internally developed and validated AI platform”, said Christophe Thurieau, Executive Director Research at Servier, in a press release. 

“I am excited to see the collaboration—it is yet another strong acknowledgment of our AI capabilities and R&D expertise”, said Zhavoronkov in the same statement. “As we deepen the integration of generative AI into every stage of the pharma value chain, I believe the future of pharmaceutical superintelligence is never so close, where AI agents could actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development.”